viatris glp-1 receptor agonist medications Comparing Ozempic, Wegovy and Other Drugs Generics Industry Hungry For More

Description

Cardiovascular diseases, though crucial, constitute a smaller share compared to the other two indications, reflecting a more specialized approach in GLP-1 drug applications for these diseases

During the GLP-1 shortages in 2022, the FDA permitted compounding to bridge supply gaps, but with shortages officially resolved there has been a lot of debate over the sale of compounded alternatives

With this in mind, here were going to take a look at the pharmacokinetics of the two big boys (WeGovy and Mounjaro) and think about the impact those may have on the expected effects with type 1, and potentially the corroloary effects when used for other conditions

Most DPP4is exhibit low and reversible plasma protein binding (ranging from 9.3% to 38%), except linagliptin (70%) and alogliptin (~100%)

More than 80 per cent of those prescribed the pill in the US had never previously used weight-loss injections, suggesting the tablets could ultimately prove even more popular than the jabs, which have already been used by more than 2.5 million Britons